Dr Asad Qureshi
- London, GB
- En, En
- Best at: Upper and lower gastro-intestinal cancers
Dr Asad Qureshi is a Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust. In his NHS and private practice, he specialises in the treatment of upper and lower gastro-intestinal cancers: Oesophageal Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Chemotherapy, SABR including CyberKnife. Dr Qureshi is the Clinical Lead for out-patients in the Cancer Centre at Guy’s Hospital, London and is a member of the Senior Oncology Management Team. He is also the Clinical Oncology and Radiotherapy Audit Lead and the Clinical Oncology Oesophago-gastric lead. He trained at St Bartholomew’s and The Royal London Hospitals medical schools where he gained a BSc in neurosciences. He completed his specialist training in Clinical Oncology at a number of specialist departments in London, including Guy’s and St Thomas’ Hospital, Charing Cross Hospital, St Bartholomew’s Hospital and The Royal Marsden Hospital. During his training spent two years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London assessing novel radiotherapy techniques for the treatment of mobile tumours. Dr Qureshi plays an active role in research and is a Principle Investigator on a number of national clinical trials. His research interests include Stereotactic Radiotherapy (SABR), Image-guided Radiotherapy (IGRT) and dose escalation of radiotherapy and he has published a number of papers in this field. Dr Qureshi is committed to medical education. He is a clinical and educational supervisor for Clinical Oncology trainees at Guy’s and St Thomas’ NHS Foundation Trust. He is also a Medical Supervisor for radiographers on prescribing courses.
Statistics.
Achievements of Dr Asad Qureshi
co-authors
About.
Information about Dr Asad Qureshi
Clinical Experience.
Academic research.
Total articles
- colorectal cancer - 2
- chemotherapy - 2
colorectal cancer articles - Impact Factor
- gastrointestinal tract - 2
- oncology therapy - 2
Colorectal cancer treatment.
Colorectal cancer is the third most common malignancy in the developed countries, and about a quarter of people present with intestinal obstruction or perforation. Risk factors for colorectal cancer are mainly dietary and genetic. Overall 5-year survival is about 50%, with half of people having surgery experiencing recurrence of the disease.

Connections.
Map of connections
co-authors